2 results
Approved WMOCompleted
Primary objective:To demonstrate the efficacy of Rifaximin -EIR 400 mg Tablet (800mg /BID, total daily dose 1600 mg) versus placebo in the prevention of endoscopic Crohn*s disease recurrence following ileocolonic resection
Approved WMOPending
To date, no dedicated prospective, randomized, blinded trials have been performed to assess the benefit of CRT in patients with NICD. It is difficult to hypothesize whether CRT implantation may be beneficial in patients with NICD. The objective of…